<DOC>
	<DOC>NCT01507337</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare the exposure of liraglutide in young versus elderly healthy subjects.</brief_summary>
	<brief_title>Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Good general health as judged by the investigator, based on medical history, physical examination including 12lead ECG (electrocardiogram), vital signs, and blood and urinary laboratory assessments Age, young subjects: age 1845 years (both incl.) Age, elderly subjects: age at least 65 years Body Mass Index (BMI) 1830 kg/m^2 (both incl.) Blood pressure, young: Diastolic 5090 mmHg, systolic 90140 mmHg Blood pressure, elderly: Diastolic 5095 mmHg, systolic 92160 mmHg History of any clinically significant renal, hepatic, cardiovascular, pulmonary, gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric disease, or other major disorders that could interfere with the objectives of the trial, as judged by the investigator Impaired renal function Any clinically significant abnormal ECG (electrocardiogram) Active hepatitis B and/or active hepatitis C Positive HIV (human immunodeficiency virus) antibodies Febrile illness within 5 days prior to first administration of liraglutide History of alcoholism or drug abuse during the last 12 months Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco products Habitual excessive consumption of methylxanthinecontaining beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>